热门资讯> 正文

Guardant已批准适用于Braftovi的Guardant 360配套诊断

2026-01-22 22:19

Guardant Health(GH) 0
辉瑞(PFE) 0

The US FDA approved Guardant Health's (GH) Guardant360 CDx companion diagnostic for use in determining which patients could benefit from Pfizer's (PFE) Braftovi (encorafenib) as a colorectal cancer treatment.
The test is used with patients with BRAF V600E-mutant metastatic colorectal cancer.
Guardant360 CDx uses a small amount of blood to find genetic mutations.

More on Guardant Health

Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth
44th Annual J.P. Morgan Healthcare Conference
Guardant Health, Inc. (GH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Guardant Health guides Q4 and FY25 revenue above consensus
Guardant Health is the top performing healthcare services stock YTD

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。